# Flavonoids as a Potential Antifungal Alternative Against Candida auris (Candidozyma auris) from Clades III and IV

**Authors:** Jonathan García-Hernández, Omar Gómez-García, Lourdes Villa-Tanaca, Dulce Andrade-Pavón

PMC · DOI: 10.3390/jof12030179 · Journal of Fungi · 2026-03-02

## TL;DR

This study explores flavonoids as a new antifungal treatment for Candida auris, a drug-resistant fungus, by testing their effectiveness and toxicity.

## Contribution

The study evaluates flavonoids as a novel antifungal alternative against specific clades of Candida auris and identifies their potential to inhibit efflux pumps.

## Key findings

- Eleven flavonoids showed dose-dependent inhibition of C. auris growth.
- Some flavonoids reduced efflux pump activity, which could enhance antifungal treatment efficacy.
- Flavonoids exhibited toxicity levels comparable to or lower than reference antifungals.

## Abstract

Candida auris is a critical emerging pathogen of high priority due to its ability to develop multidrug resistance to various antifungals. Given the increase in cases associated with C. auris, it is essential to evaluate new candidates with antifungal potential. In this context, flavonoids represent a promising source for the development of new therapeutic alternatives. In this study eleven flavonoids were evaluated for their antifungal activity against C. auris strains from clades III and IV. The flavonoids showed dose-dependent inhibition of C. auris growth. Toxicity tests were conducted using the in vivo Tenebrio molitor model. The flavonoids exhibited toxicity levels either comparable to or lower than reference antifungals. Also, the study examined the ability of the flavonoids to inhibit efflux pumps. Some of the flavonoids (quercetin, fisetin, hesperetin, luteolin and apigenin) reduced efflux pump activity, which is an important feature since these pumps actively expel antifungal drugs from the cell, reducing the drug’s effectiveness. This suggests that the flavonoids might inhibit efflux pump activity, potentially enhancing the efficacy of antifungal treatments. The study supports the potential of flavonoids as new therapeutic agents for C. auris. Since they target efflux pumps, which are a significant mechanism of resistance in C. auris, flavonoids could be used either alone or in combination with existing antifungals to improve treatment outcomes.

## Linked entities

- **Chemicals:** quercetin (PubChem CID 5280343), fisetin (PubChem CID 5281614), hesperetin (PubChem CID 3593), luteolin (PubChem CID 5280445), apigenin (PubChem CID 5280443)
- **Species:** Tenebrio molitor (taxon 7067)

## Full-text entities

- **Diseases:** III (MESH:C537189), injury to (MESH:D014947), infections (MESH:D007239), Fungal infections (MESH:D009181), endometriosis (MESH:D004715), deaths (MESH:D003643), TM (MESH:D001260), Toxicity (MESH:D064420), candidemia (MESH:D058387), mitochondrial impairment (MESH:D028361), C. auris (MESH:C000656864), multidrug resistance (MESH:D018088), gastrointestinal complications (MESH:D005767), IV (MESH:D006011), inflammatory (MESH:D007249)
- **Chemicals:** hesperetin (MESH:C013015), pyrimidine (MESH:C030986), apigenin (MESH:D047310), epigallocatechin (MESH:C057580), YD liquid medium (-), proton (MESH:D011522), rutin (MESH:D012431), azole (MESH:D001393), echinocandins (MESH:D054714), DMSO (MESH:D004121), PBS (MESH:D007854), naringenin (MESH:C005273), luteolin (MESH:D047311), polyenes (MESH:D011090), Fluconazole (MESH:D015725), baicalein (MESH:C006680), Fisetin (MESH:C017875), verapamil (MESH:D014700), Flavonoid (MESH:D005419), ATP (MESH:D000255), flavone (MESH:C043562), MOPS (MESH:C008550), catechin (MESH:D002392), R6G (MESH:C026188), amphotericin B (MESH:D000666), water (MESH:D014867), glycerol (MESH:D005990), caspofungin (MESH:D000077336), agar (MESH:D000362), Glucose (MESH:D005947), NaCl (MESH:D012965), itraconazole (MESH:D017964), quercetin (MESH:D011794)
- **Species:** Pichia kudriavzevii (species) [taxon 4909], Candidozyma haemuli (species) [taxon 45357], Petrachloros mirabilis (species) [taxon 2918835], Candidozyma auris (species) [taxon 498019], Nakaseomyces glabratus (species) [taxon 5478], Homo sapiens (human, species) [taxon 9606], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Tenebrio molitor (yellow mealworm, species) [taxon 7067], Candida albicans (species) [taxon 5476], Nakaseomyces glabratus CBS 138 (strain) [taxon 284593]
- **Cell lines:** CJ97 — Homo sapiens (Human), Diffuse large B-cell lymphoma germinal center B-cell type, Cancer cell line (CVCL_UI83), 20- — Aedes aegypti (Yellowfever mosquito), Spontaneously immortalized cell line (CVCL_Z353), 20-1498 — Homo sapiens (Human), Soft tissue fibrosarcoma, Cancer cell line (CVCL_ZZ51)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028025/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028025/full.md

## References

62 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028025/full.md

---
Source: https://tomesphere.com/paper/PMC13028025